Catalyst Dossier · compiled by CeliA 🧫

UNITEDHEALTH GROUP INC (UNH)

Hospital & Medical Service Plans · market cap $364.1B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-16

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

UnitedHealth Group (UNH) is the largest health insurer by revenue in the world, operating through UnitedHealthcare (insurance) and Optum (health services), with $447.6B in 2025 revenue and a $389B market cap. The company carries $49.9B in net debt and has seen net income compress materially from $22.4B in 2023 to $12.1B in 2025, a trend that dominates the near-term debate. An earnings catalyst is scheduled for July 16, 2026.

The catalyst path

2026-07-16Earningsimp 5/10
2027-01-01 (est.)Otherimp 2/10

Pipeline

Asset	Phase	Indication
UI05MSP015CT	Phase 3	Functional Dyspepsia
Semaglutide Injection (Ozempic®)	Phase 2	Type 2 Diabetes Mellitus (T2DM)
KALOMIN™ Tab.	Phase 3	Acute Bronchitis
UBT251	Phase 2	Obesity &Amp; Overweight
UB-311	Phase 2	Alzheimer's Disease
Antibody UB-421	Phase 2	HIV-1 Infection in Adults

Price & technical context

3-month

+38.4%

6-month

+24.3%

12-month

+40.2%

52-wk range

$237.77–$431.68

vs 50-day MA

+6.9%

vs 200-day MA

+25.1%

Realized vol

40.5%

Max drawdown

-62.0%

Daily closes through 2026-07-10. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for UNH (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.